Professor Borislava Mihaylova
Borislava Mihaylova
MSc, DPhil
Professor of Health Economics
- Health Economics Research Centre
Borislava (Boby) Mihaylova is Professor of Health Economics at the Health Economics Research Centre in Oxford Population Health.
Her research programme focuses on economic aspects of chronic disease (such as cardiovascular, chronic kidney disease and diabetes) and comprises studies of the impact of disease events and interventions on morbidity, mortality, health-related quality of life and healthcare costs; development of disease models to evaluate long-term effects of disease and interventions, cost-effectiveness analyses of healthcare interventions and studies of socio-economic determinants of health.
She is leading/has led the development of the economic analyses in a number of large randomised controlled trials (EMPA-KIDNEY, ACST-2, REVEAL, SHARP, THRIVE) and in the individual participant data meta-analysis of statin trials (Cholesterol Treatment Collaboration).
Her work on effectiveness and cost-effectiveness of statins for cardiovascular disease prevention in the Heart Protection Study and the Cholesterol Treatment Collaboration has been influential in informing treatment recommendations for people at different vascular disease risk.
Recent publications
-
Quality of life of primary caregivers by severity and control of children's asthma: a systematic review and meta-analysis.
Journal article
Tomini F. et al, (2025), Qual Life Res, 34, 3425 - 3445
-
2025 ESC/EACTS Guidelines for the management of valvular heart disease.
Journal article
Praz F. et al, (2025), Eur Heart J, 46, 4635 - 4736
-
Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling study.
Journal article
Jamieson T. et al, (2025), Eur J Health Econ
-
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.
Journal article
Mach F. et al, (2025), Eur Heart J, 46, 4359 - 4378
-
Assessment of adverse effects attributed to statin therapy in product labels: Meta-analysis of placebo-controlled randomised trials
Journal article
REITH C. et al, (2025), The Lancet
